Reduces risk of diabetes complications. Poor management can lead to stroke, renal failure, Source: Diabetes Control and Complications Trial. Optimizing …
r
Roche Diabetes Care Innovating blood glucose monitoring to allow people with diabetes to Live Life The Way they Want
Staffan Ek Head of Roche Diabetes Care
Goldman Sachs Diabetes Conference, London, 4th September 2003
Diabetes market Roche Diagnostics Blood glucose market A person with diabetes view Roche Diabetes Care solutions
Diagnostics
2
r
Diabetes is a global epidemic 95 million undiagnosed one half of the market
Type 1 Type 2 10 autoimmune mediated 90 peripheral insulin resistent
324
72
189
2003
Sources: Diabetes IDF Atlas / Zimmet, P, IDF Congress August 2003
2025
3
Diagnostics
r
Early diagnosis and effective control
Reduces risk of diabetes complications
Poor management can lead to stroke, renal failure, amputation, blindness Tight blood glucose control can prevent or delay onset and progression of complications People must be able to easily monitor blood glucose to manage their diabetes Of those monitoring blood glucose, only half test as recommended
Diagnostics
4
r
Source: Diabetes Control and Complications Trial; DCCT, Roche analysis
Optimizing diagnostic monitoring
Potential reduction in side-effects
by lowering HbA1c down to 7
microvascular endpoints were reduced significantly
Neuropathy
Retinopathy
Nephropathy
-65 -60 -55 -50 -45
5
Source: Diabetes Control and Complications Trial
Diagnostics
r
In-vitro diagnostics world market 2002 Glucose monitoring one of the largest market segments
Blood glucose monitoring highly competitive under-penetrated fast growing highly profitable very visible
Molecular Dx 4 Near Pt Testing 11 other 21
Source: Roche analysis, Boston Biomedical Consultants, 2002 figures, CAGR 2002 2007 Other includes Haematology, Coagulation, Urinalysis
world IVD market USD 229 million CAGR 7
Diabetes Monitoring 20
Immuno assays 27
Clinical Chemistry 15
Diagnostics
6
r
Roche Diabetes Care
Continually gaining market share
others Abbott Bayer Lifescan JJ
34 35 36 37
Roche
1999
Note: Source:
2000
2001
2002
other includes Generics, private label including Abbotts activities, KDK, Therasense, other manufacturers Roche analysis - market share tracking 14 key countries blood glucose monitoring systems
Diagnostics
7
r
Roche Diabetes Care: most profitable second fastest growing segment
6,900 14 10 7,239 11 5
6,252 12 18
2,026
CHF m local currencies
growth CHF
2,333
2,511
Diabetes Care Molecular Dx Applied Science Near Patient Ttg Centralized Dx
14 8 19 11 7 1 5 0
margins
750 511 528
877 571 591
977 574 590
2,437
2,528
2,587
8 2
2000
2001
2002
Diagnostics
8
r
Diabetes market and Roche Diagnostics Blood glucose market A person with diabetes view Roche Diabetes Care solutions
Diagnostics
9
r
Blood glucose market
Sustained double digit growth
local CAGR 1995 - 2002 14
180 160 140
CHF million
CAGR 00 - 05 CAGR 05 - 10 11 10
146
120 100 80 60 40 20 00 1998 1999 2000 2001 2002 43 48 57 65 69
95
2005
2010
local growth
Note: Source:
14
14
12
12
includes, lancets, diabetes urine testing, other Roche analysis
Diagnostics
10
r
Blood glucose monitoring is 30 of the overall diabetes market
80
CHF 21 billion 2001
50 15
65
30
glucose monitoring insulin delivery insulin
orals diabetes therapy
Source: Roche analysis
Diagnostics
11
r
Blood glucose market
Drivers of glucose strip growth
growth drivers of blood glucose strip usage penetration of blood glucose monitoring aging / obesity test frequency
test frequency testing penetration aging/ obesity other
today
Source: Roche
analysis
2010
12
Diagnostics
r
Blood glucose strip consumption by therapeutic choice
2004
100 23 80 60 40 20 0 23 5
PwD Strip Volume
2013
100 80 60 40 20 0 18 7
PwD Strip Volume
29 75
72
Non-insulin Therapy 43 Conventional Therapy Intensified Conventional Therapy 34
33
38
Non-insulin Conventional Intensive Total MM
Note: PwD People with Diabetes Source: Roche Analysis
57 18 4 79
2,910 5,560 4,430 12,900
Non-insulin Conventional Intensive Total MM
101 24 10 135
9,080 10,260 12,00 
0 31,340 13
Diagnostics
r
Blood glucose systems
Market drivers
Increased ease of use eg test strip integration Smaller amounts of blood total time to result Tailoring to individual needs eg talking meter, discrete Minimised lancet pain
Improved data management eg, use of Palm type devices, Internet downloading and data keeping
Diagnostics
14
r
Diabetes market Roche Diagnostics Blood glucose market A person with diabetes view Roche Diabetes Care solutions
Diagnostics
15
r
Diagnosis
First step to disease management
Diagnosis of Diabetes
high blood glucose levels 10 90
type 1 blood glucose tested 3-6 times day 100 insulin treatment glycated
hemoglobin HbA1c quarterly
type 2 blood glucose tested daily to thrice weekly 80 combination diet, exercise and orals 20 insulin treatment glycated hemoglobin HbA1c quarterly
16
Diagnostics
r
A patients view
Managing Diabetes rules their life
Daily self-care activities burdensome self-monitoring of blood glucose, injections Unending: 365-days a year lifelong proposition Lifestyle changes required diet, exercise Good behaviour does not always pay off Balancing quality of life in the present and future health
Diagnostics
17
r
Influences on buying decision of people with Diabetes
Increasing self-choice as consumers become more experienced Healthcare Professionals Drs nurses remain important influencers, especially for newly diagnosed people In some markets, role of employers seems to increase Increasing role of payer groups / government in recent years
Retail / Pharmacist 20 Other 22
Buying Decision Influencers
HCP 40
Product 39
Self Choice 40
Brand / Promotion 39
influence on meter choice
influence on self choice 18
Source: Roche analysis
Diagnostics
r
Diabetes market Roche Diagnostics Blood glucose market A person with diabetes view Roche
Diabetes Care solutions
Diagnostics
19
r
Future market: a steady stream of diabetes innovations market evolution
Spot Monitoring
bGM innovation continues with
microsampling, handling step integration and improved diabetes management information smart meters
Handling Reduction
1-Step bGM Smart bGM
Alternative Site
Continuous Monitoring CM is initially launched as a professional
product, then becomes a consumer product the 2nd half of the decade
Continuous Monitoring
Automated Pancreas AP emerges
as a product at the end of the decade
Professional CM
Consumer CM
acceptance if they turn out to be accurate and convenient
Complete Solutions
Non-invasive technologies show little promise currently, but will gain
Open-loop AP Early Islet Cell 08
Individual / Payer preferences will dictate choices, eg price, type of
information, degree of hands-on management, definition of convenience
00
01
02
03
04
05
06
07
Note: Automated Pancreas still requires consumer interaction and intervention
Diagnostics
20
r
Roche Diabetes Care strategy
Single Strip System
Advantage Advantage
Active
e-Diabetes
i-Net Advisor
Insulin Pumps Active
Compact AST Compact
II
Integrated Spot Monitoring
i-Net
CM
Compact AST Compact II
Advisor
Automated Pancreas
21
Diagnostics
r
Integrated spot monitoring
Integrating meter, lancet and strips
Accu-Chek Compact fully automated strip handling 17 test strip drum fully integrated / all-in-one system accurate reading in only 8 seconds 15 L sample volume future growth through integrated lancet
Roche leading development of new market segment
22
Diagnostics
r
e-Diabetes
Helping in the management of health information
Diagnostics
23
r
Continuous Glucose Monitoring
GlucOnline subcutaneous continuous glucose monitoring for professional use for people with diabetes on intensive therapy
Diagnostics
24
r
Automated pancreas vision
Enabling near-normal glycemic control
bGM
continuous monitoring
insulin pump
automated pancreas
increased medical device sophistication
Continuous monitoring insulin algorithms are the missing pieces of the AP equation
25
Diagnostics
r
r
r
Source:aetna.com
